IN2015DN04151A - - Google Patents

Info

Publication number
IN2015DN04151A
IN2015DN04151A IN4151DEN2015A IN2015DN04151A IN 2015DN04151 A IN2015DN04151 A IN 2015DN04151A IN 4151DEN2015 A IN4151DEN2015 A IN 4151DEN2015A IN 2015DN04151 A IN2015DN04151 A IN 2015DN04151A
Authority
IN
India
Prior art keywords
same
formulations
compositions
methods
acid esters
Prior art date
Application number
Other languages
English (en)
Inventor
Dechi Guan
David I Macdonald
Original Assignee
Methylation Sciences Internat Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylation Sciences Internat Srl filed Critical Methylation Sciences Internat Srl
Publication of IN2015DN04151A publication Critical patent/IN2015DN04151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
IN4151DEN2015 2012-10-17 2013-10-16 IN2015DN04151A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715138P 2012-10-17 2012-10-17
PCT/CA2013/000876 WO2014059522A1 (en) 2012-10-17 2013-10-16 Compositions comprising s-adenosylmethionine and a gallic acid ester

Publications (1)

Publication Number Publication Date
IN2015DN04151A true IN2015DN04151A (enrdf_load_html_response) 2015-10-16

Family

ID=50487370

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4151DEN2015 IN2015DN04151A (enrdf_load_html_response) 2012-10-17 2013-10-16

Country Status (15)

Country Link
US (7) US9801896B2 (enrdf_load_html_response)
EP (2) EP2753336B1 (enrdf_load_html_response)
JP (2) JP5877935B2 (enrdf_load_html_response)
KR (2) KR20160094451A (enrdf_load_html_response)
CN (2) CN104884067B (enrdf_load_html_response)
AU (1) AU2013332209B2 (enrdf_load_html_response)
CA (1) CA2888302C (enrdf_load_html_response)
DK (1) DK2753336T3 (enrdf_load_html_response)
ES (1) ES2540581T3 (enrdf_load_html_response)
HK (1) HK1217909A1 (enrdf_load_html_response)
IL (1) IL243585A0 (enrdf_load_html_response)
IN (1) IN2015DN04151A (enrdf_load_html_response)
RU (2) RU2586300C1 (enrdf_load_html_response)
SG (1) SG11201503048TA (enrdf_load_html_response)
WO (1) WO2014059522A1 (enrdf_load_html_response)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840472B2 (en) 2016-05-03 2023-12-12 Heraeus Quartz North America Llc Elongation method and preform for producing an optical glass component

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884067B (zh) 2012-10-17 2016-09-07 甲基化物科学国际有限公司 包含s-腺苷甲硫氨酸及没食子酸酯的组合物
EP3131557A4 (en) * 2014-04-14 2018-05-02 Methylation Sciences International SRL Novel ademetionine formulations
RU2587331C1 (ru) * 2015-06-19 2016-06-20 Общество с ограниченной ответственностью "Полигепазол" Способ получения фармацевтической композиции адеметионина и его лекарственной формы
CN105232515A (zh) * 2015-10-10 2016-01-13 齐齐哈尔医学院 没食子酸乙酯用于制备治疗人结肠癌凋亡药物的应用
CN105476982A (zh) * 2016-02-02 2016-04-13 张干 没食子酸的新用途
CN108853085A (zh) * 2017-05-15 2018-11-23 苏州凯祥生物科技有限公司 儿茶素类和表儿茶素类化合物用于上调MicroRNA-126表达水平的用途
CN111265509A (zh) * 2020-02-19 2020-06-12 齐鲁工业大学 没食子酸衍生物防治动脉粥样硬化疾病的应用
CN114931571A (zh) * 2022-03-30 2022-08-23 上海中医药大学附属曙光医院 没食子酸甲酯在制备骨关节炎治疗药物中的应用
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37913B1 (en) 1972-08-02 1977-11-09 Bioresearch Sas Salt of s-adenosyl-l-methionine
IE39517B1 (en) 1973-06-27 1978-10-25 Bioresearch Sas Double salts of s-adenosyl-l-methhionine
AR221676A1 (es) 1974-07-12 1981-03-13 Bioresearch Sas Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico
US5264446A (en) 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US4525345A (en) 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
DE3435325A1 (de) 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
IT1169772B (it) 1983-08-24 1987-06-03 Bioresearch Spa Composizioni terapeutiche per uso orale contenenti sali stabili della s-adenosil-l-metionina
US4680323A (en) 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4537772A (en) 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
IT1173992B (it) 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
US4601894A (en) 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4687757A (en) 1986-03-24 1987-08-18 Phillips Petroleum Company Hydrofining catalyst composition and process for its preparation
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5200193A (en) 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
FR2623396B1 (fr) 1987-11-25 1990-03-30 Sanofi Sa Utilisation de l'ademetionine contre le vieillissement de la peau
US5169642A (en) 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
GB8900812D0 (en) 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
IT1229477B (it) 1989-03-13 1991-09-03 Bioresearch Spa Impiego di 5' deossi - 5' metiltioadenosina, s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a ridurre la seborrea e composizioni farmaceutiche relative
US5137712A (en) 1990-08-31 1992-08-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
IT1243859B (it) 1990-10-23 1994-06-28 Bioresearch Spa Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
IL104192A (en) 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
JPH05271067A (ja) 1992-03-24 1993-10-19 Takeda Chem Ind Ltd 線維化抑制剤
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
RU2018314C1 (ru) 1993-07-15 1994-08-30 Приморское научное медико-техническое общество Средство для лечения экземы
JPH11506426A (ja) 1995-04-25 1999-06-08 オリディグム コーポレイション 代謝経路のｓ−アデノシルメチオニン調節ならびに診断および治療におけるその使用
DE19631085A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US5877935A (en) 1996-09-17 1999-03-02 Honda Giken Kogyo Kabushiki-Kaisha Active carbon used for electrode for organic solvent type electric double layer capacitor
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6555141B1 (en) 1998-02-27 2003-04-29 Nutramax Laboratories, Inc. L-ergothioneine, Milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
DE19839443A1 (de) 1998-08-29 2000-03-02 Miklos Ghyczy Arnzneimittel mit entzündungshemmender Wirkung
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6635615B1 (en) 1999-11-17 2003-10-21 Rolland F. Hebert Stable salts of S-adenosyl-l-methionine
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
CA2405360A1 (en) 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US6944766B2 (en) 2000-05-02 2005-09-13 Canon Kabushiki Kaisha Information processing apparatus
FI113942B (fi) 2000-08-18 2004-07-15 Control Ox Oy Kasviperäisten fenolisten yhdisteiden käyttö valmistettaessa klamydiainfektion hoidossa ja ennaltaehkäisyssä käyttökelpoista farmaseuttista valmistetta, terveyteen myönteisesti vaikuttavaa ravintoainekoostumusta tai koostumusta lisättäväksi tällaisiin elintarvikkeisiin
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6759395B2 (en) 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
AU2002228321A1 (en) 2000-12-18 2002-07-01 Orchid Chemicals And Pharmaceuticals Limited A novel soft-gelatin capsule comprising s-adenosylmethionine and a method for producing the same
GB0109428D0 (en) 2001-04-17 2001-06-06 Process & Ind Design Consultan Therapeutic compositions
GB0111579D0 (en) 2001-05-11 2001-07-04 Holford & Associates Ltd Oral supplement
JP3908513B2 (ja) 2001-11-19 2007-04-25 日本甜菜製糖株式会社 肝機能改善剤
DE60326709D1 (de) 2002-04-29 2009-04-30 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
WO2005030181A1 (en) 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
KR20060085686A (ko) 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
BRPI0416138A (pt) 2003-10-31 2007-01-02 Alza Corp composições e formas de dosagem para a absorção realçada de gabapentina e pregabalina
EP1701705A4 (en) 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE
WO2005065661A2 (en) 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
US7429569B2 (en) 2004-01-29 2008-09-30 Fast Balance, Inc. Compositions and methods for the regulation of homocysteine levels within the body
US20050181047A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US8263574B2 (en) 2004-09-29 2012-09-11 James L. Schaller, P.A. Topical formulations for the treatment of depression with S adenosyl methionine
US20080020041A1 (en) 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
US20060127506A1 (en) 2004-12-10 2006-06-15 Hebert Rolland F Compositions of S-adenosyl-L-methionine
US20060280789A1 (en) 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US8063024B2 (en) 2005-01-26 2011-11-22 University Of Manitoba Use of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
PL1731596T3 (pl) 2005-06-09 2013-08-30 Gnosis Spa Suszone, liofilizowane i/lub mikrokapsułkowane komórki Saccharomyces cerevisiae o dużej zawartości (S)-(+)-S-adenozylo-L-metioniny
JP5095615B2 (ja) 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
KR101393652B1 (ko) 2006-02-09 2014-05-14 알바 쎄러퓨틱스 코포레이션 폐쇄연접 효과기용 제제
AR059423A1 (es) 2006-02-09 2008-04-09 Univ Maryland Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
GB0603252D0 (en) 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US20070265211A1 (en) 2006-05-12 2007-11-15 Matthias Rath Novel composition and method effective in inhibiting the atherogenic process
WO2008006581A2 (en) 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions and use thereof for the treatment, co-treatment or prevention of imflammatory disorders
US20100062073A1 (en) 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
BRPI0720982A2 (pt) 2006-12-28 2014-03-11 Microbiotech Inc Composições farmacêuticas de galatos de alquila
US20090088404A1 (en) 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
CN101012336A (zh) * 2007-01-31 2007-08-08 浙江大学 含植物油的高强度可降解谷类蛋白质塑料及其制备方法
US20090197824A1 (en) 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
CN101677543A (zh) 2007-01-31 2010-03-24 甲基化物科学国际有限公司 S-腺苷甲硫氨酸的延时释放药物制剂
US20080279931A1 (en) 2007-05-09 2008-11-13 Northern Holdings Inc. Composition for treatment of pain
ITMI20081405A1 (it) 2008-07-29 2010-01-30 Velleja Res Srl Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia
CA2769682C (en) 2008-08-01 2015-03-03 Nikolajs Volkovs System and method for the calculation of a polynomial-based hash function and the erindale-plus hashing algorithm
WO2010027014A1 (ja) 2008-09-04 2010-03-11 株式会社カネカ Ｓ－アデノシル－ｌ－メチオニンの吸収性を高める方法およびｓ－アデノシル－ｌ－メチオニンの吸収性が高められた組成物
EP2193787A1 (en) 2008-12-02 2010-06-09 Giorgio Stramentinoli Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
WO2012012902A1 (en) * 2010-07-28 2012-02-02 Msi Methylation Sciences Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20110064712A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
WO2012170488A1 (en) 2011-06-07 2012-12-13 Zx Pharma, Llc Multiparticulate s-adenosylmethionine compositions and related methods
CN104884067B (zh) 2012-10-17 2016-09-07 甲基化物科学国际有限公司 包含s-腺苷甲硫氨酸及没食子酸酯的组合物
WO2014089174A2 (en) 2012-12-06 2014-06-12 Aerodesigns, Inc. Aerosol dispenser with edible cartridge
US20150087679A1 (en) 2013-09-20 2015-03-26 Hany Helmi Nutritional sleep supplement
AU2015247815A1 (en) 2014-04-14 2016-11-03 Flex Pharma, Inc. Ion channel activators and methods of use
EP3131557A4 (en) 2014-04-14 2018-05-02 Methylation Sciences International SRL Novel ademetionine formulations
JP2015214518A (ja) 2014-05-12 2015-12-03 ライオン株式会社 睡眠の質を改善する方法及び睡眠の質の改善用の経口用組成物
US20180000881A1 (en) 2015-01-22 2018-01-04 Bob Fritz Phosphatidylserine-Containing Diet Supplement Aids With Melatonin Anti-Catabolic Dietary Nutrients
RU2587331C1 (ru) 2015-06-19 2016-06-20 Общество с ограниченной ответственностью "Полигепазол" Способ получения фармацевтической композиции адеметионина и его лекарственной формы
CN105232515A (zh) 2015-10-10 2016-01-13 齐齐哈尔医学院 没食子酸乙酯用于制备治疗人结肠癌凋亡药物的应用
US10449148B2 (en) 2015-11-04 2019-10-22 Braingear Enterprises, Inc. Dietary supplement for improving brain health
CN105476982A (zh) 2016-02-02 2016-04-13 张干 没食子酸的新用途
US20200246404A1 (en) 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
CN108853085A (zh) 2017-05-15 2018-11-23 苏州凯祥生物科技有限公司 儿茶素类和表儿茶素类化合物用于上调MicroRNA-126表达水平的用途
WO2019010254A1 (en) 2017-07-07 2019-01-10 President And Fellows Of Harvard College METHOD OF TREATING A DAMAGE INDUCED BY SLEEP
CN111265509A (zh) 2020-02-19 2020-06-12 齐鲁工业大学 没食子酸衍生物防治动脉粥样硬化疾病的应用
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840472B2 (en) 2016-05-03 2023-12-12 Heraeus Quartz North America Llc Elongation method and preform for producing an optical glass component

Also Published As

Publication number Publication date
US9925208B2 (en) 2018-03-27
US8975238B2 (en) 2015-03-10
JP6280535B2 (ja) 2018-02-14
JP5877935B2 (ja) 2016-03-08
RU2016117290A (ru) 2018-10-23
WO2014059522A1 (en) 2014-04-24
US9801896B2 (en) 2017-10-31
US20200129537A1 (en) 2020-04-30
JP2015533367A (ja) 2015-11-24
CN104884067B (zh) 2016-09-07
KR101748053B1 (ko) 2017-06-15
US20190022119A1 (en) 2019-01-24
US20150164935A1 (en) 2015-06-18
CN104884067A (zh) 2015-09-02
CN106074589A (zh) 2016-11-09
US20150283161A1 (en) 2015-10-08
US20220193107A1 (en) 2022-06-23
EP2949331A1 (en) 2015-12-02
IL243585A0 (en) 2016-02-29
KR20150104559A (ko) 2015-09-15
US20140220129A1 (en) 2014-08-07
ES2540581T3 (es) 2015-07-10
JP2016074725A (ja) 2016-05-12
CA2888302C (en) 2016-05-31
AU2013332209B2 (en) 2016-02-04
AU2013332209A1 (en) 2015-05-28
US12303524B2 (en) 2025-05-20
HK1217909A1 (en) 2017-01-27
US20250275997A1 (en) 2025-09-04
EP2753336A1 (en) 2014-07-16
SG11201503048TA (en) 2015-06-29
HK1199836A1 (en) 2015-10-09
KR20160094451A (ko) 2016-08-09
RU2586300C1 (ru) 2016-06-10
CA2888302A1 (en) 2014-04-24
EP2753336B1 (en) 2015-05-06
EP2753336A4 (en) 2014-09-03
DK2753336T3 (en) 2015-07-27

Similar Documents

Publication Publication Date Title
IN2015DN04151A (enrdf_load_html_response)
WO2014004993A3 (en) Methods of reducing ldl-p
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
TN2014000540A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
IN2015DN00376A (enrdf_load_html_response)
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
AR091006A1 (es) Formulaciones de testosterona proliposomal
NZ702799A (en) Methods and compositions for cns delivery of arylsulfatase a
IN2014DN00277A (enrdf_load_html_response)
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
IN2014CN04009A (enrdf_load_html_response)
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
HK1183814A (en) Combination therapy methods for treating proliferative diseases
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
MX357329B (es) Extracto crudo de un hibrido de sechium edule, metodo para su extraccion y su uso para formulaciones con efecto antineoplasico.